Novel Proteins from the Sand Fly <i>Lutzomyia longipalpis</i> are Potent Inhibitors of Complement Activity

This invention relates to the discovery that five proteins from the salivary glands of Lutzomyia longipalpis, LJM04, LJM11, LJM19, LJM26, and LJL143 have anti-complement activity. These proteins demonstrate potent inhibition of both the classical and alternative pathways for complement activation. All proteins, excluding LJM19, were shown to bind and inhibit the C3b molecule, thus inactivating an integral component of the complement pathway.

The complement system is a very important line of defense against pathogens, and is involved in many pathologies and syndromes affecting human health. It is therefore envisioned that these five novel proteins may be used to treat conditions where the complement system is involved including lupus erythematosus, juvenile arthritis, and complications associated with cardiac surgery and hemodialysis.

Potential Commercial Applications: Competitive Advantages:
  • Potent inhibition of complement activity
  • Treatment of diseases involving the complement system

Jesus Valenzuela (NIAID)

Intellectual Property:
US Application No. 61/142,098
PCT Application No. PCT/US2009/069874

Licensing Contact:
John Stansberry , Ph.D.
NIH Office of Technology Transfer
Phone: 301-435-5236

OTT Reference No: E-205-2008/0

Updated: Jun-03-2010